WO2010042997A1 - Compositions and methods for treatment of kidney disorders - Google Patents
Compositions and methods for treatment of kidney disorders Download PDFInfo
- Publication number
- WO2010042997A1 WO2010042997A1 PCT/AU2009/001367 AU2009001367W WO2010042997A1 WO 2010042997 A1 WO2010042997 A1 WO 2010042997A1 AU 2009001367 W AU2009001367 W AU 2009001367W WO 2010042997 A1 WO2010042997 A1 WO 2010042997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vip
- kidney
- fibrosis
- subject
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
Claims
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2011004031A MX336384B (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney disorders. |
US13/124,139 US8569235B2 (en) | 2008-10-17 | 2009-10-16 | Treatment of kidney disorders with VIP fragments |
RU2011114857/15A RU2519124C2 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods of treating renal disorders |
AU2009304595A AU2009304595B2 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney disorders |
CN2009801410744A CN102186496A (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney disorders |
JP2011531304A JP2012505835A (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for the treatment of renal disorders |
EP09820116.3A EP2349320B1 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney disorders |
KR1020117011192A KR101671406B1 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney disorders |
NZ592612A NZ592612A (en) | 2008-10-17 | 2009-10-16 | Vasoactive intestinal peptide (VIP) Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-X for the treatment of kidney disorders |
DK09820116.3T DK2349320T3 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for the treatment of renal disorders |
BRPI0914504A BRPI0914504B8 (en) | 2008-10-17 | 2009-10-16 | use of a vasoactive intestinal peptide (piv) or one or more functional fragments of the piv |
CA2740989A CA2740989C (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney fibrosis comprising vasoactive intestinal peptide (vip) or functional vip fragments |
ES09820116.3T ES2603963T3 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for the treatment of renal disorders |
IL212353A IL212353A0 (en) | 2008-10-17 | 2011-04-14 | Compositions and methods for treatment of kidney disorders |
ZA2011/03572A ZA201103572B (en) | 2008-10-17 | 2011-05-16 | Compositions and methods for treatment of kidney disorders |
HK12100865.8A HK1160598A1 (en) | 2008-10-17 | 2012-01-31 | Compositions and methods for treatment of kidney disorders |
US14/034,706 US9238054B2 (en) | 2008-10-17 | 2013-09-24 | Treatment of kidney fibrosis with VIP fragments |
IL235888A IL235888A (en) | 2008-10-17 | 2014-11-25 | Use of vasoactive intestinal peptide (vip) fragments in the manufacture of compositions for treatment of kidney fibrosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008905378A AU2008905378A0 (en) | 2008-10-17 | Compositions and methods for treatment of kidney disorders | |
AU2008905378 | 2008-10-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/124,139 A-371-Of-International US8569235B2 (en) | 2008-10-17 | 2009-10-16 | Treatment of kidney disorders with VIP fragments |
US14/034,706 Division US9238054B2 (en) | 2008-10-17 | 2013-09-24 | Treatment of kidney fibrosis with VIP fragments |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010042997A1 true WO2010042997A1 (en) | 2010-04-22 |
Family
ID=42106133
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2009/001367 WO2010042997A1 (en) | 2008-10-17 | 2009-10-16 | Compositions and methods for treatment of kidney disorders |
Country Status (19)
Country | Link |
---|---|
US (2) | US8569235B2 (en) |
EP (1) | EP2349320B1 (en) |
JP (1) | JP2012505835A (en) |
KR (1) | KR101671406B1 (en) |
CN (1) | CN102186496A (en) |
AU (1) | AU2009304595B2 (en) |
BR (1) | BRPI0914504B8 (en) |
CA (1) | CA2740989C (en) |
DK (1) | DK2349320T3 (en) |
ES (1) | ES2603963T3 (en) |
HK (1) | HK1160598A1 (en) |
IL (2) | IL212353A0 (en) |
MX (1) | MX336384B (en) |
MY (1) | MY160560A (en) |
NZ (2) | NZ592612A (en) |
RU (1) | RU2519124C2 (en) |
SG (1) | SG10201501316VA (en) |
WO (1) | WO2010042997A1 (en) |
ZA (1) | ZA201103572B (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010111753A1 (en) * | 2009-04-02 | 2010-10-07 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of aortic fibrosis |
WO2012042061A1 (en) * | 2010-10-01 | 2012-04-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the progression and treating a chronic kidney disease in a patient |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US8729018B2 (en) | 2005-12-20 | 2014-05-20 | Duke University | Therapeutic agents comprising elastic peptides |
WO2016145478A1 (en) | 2015-03-18 | 2016-09-22 | Vectus Biosystems Limited | Compositions for the treatment of kidney and/or liver disease |
US9821036B2 (en) | 2008-06-27 | 2017-11-21 | Duke University | Therapeutic agents comprising a GLP-2 peptide and elastin-like peptides |
US10258700B2 (en) | 2005-12-20 | 2019-04-16 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8470778B2 (en) * | 2005-12-09 | 2013-06-25 | Vectus Biosystems Limited | VIP fragments and methods of use |
SG10201501316VA (en) * | 2008-10-17 | 2015-05-28 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of kidney disorders |
CN104130663B (en) * | 2014-06-27 | 2017-01-04 | 南安市永腾技术咨询有限公司 | A kind of metal anti-corrosion paint for packer and preparation method thereof |
US9852091B2 (en) | 2015-11-16 | 2017-12-26 | International Business Machines Corporation | Techniques for handling interrupts in a processing unit using virtual processor thread groups and software stack levels |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105765A2 (en) * | 2002-06-12 | 2003-12-24 | The Board Of Trustees Of The University Of Illinois | Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds |
WO2004048401A1 (en) * | 2002-11-27 | 2004-06-10 | Itoham Foods Inc. | Peptides and medicinal compositions containing the same |
WO2006012394A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
WO2007065226A1 (en) * | 2005-12-09 | 2007-06-14 | Vectus Biosystems Limited | Vip fragments and methods of use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2573439C (en) * | 2004-06-11 | 2014-12-09 | Vectus Biosystems Limited | Compositions and methods for treating myocardial fibrosis comprising vasoactive intestinal peptide |
SG10201501316VA (en) * | 2008-10-17 | 2015-05-28 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of kidney disorders |
MX2011010341A (en) * | 2009-04-02 | 2012-01-27 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of aortic fibrosis. |
-
2009
- 2009-10-16 SG SG10201501316VA patent/SG10201501316VA/en unknown
- 2009-10-16 CN CN2009801410744A patent/CN102186496A/en active Pending
- 2009-10-16 CA CA2740989A patent/CA2740989C/en active Active
- 2009-10-16 KR KR1020117011192A patent/KR101671406B1/en active IP Right Grant
- 2009-10-16 US US13/124,139 patent/US8569235B2/en active Active
- 2009-10-16 ES ES09820116.3T patent/ES2603963T3/en active Active
- 2009-10-16 NZ NZ592612A patent/NZ592612A/en unknown
- 2009-10-16 MY MYPI2011001651A patent/MY160560A/en unknown
- 2009-10-16 WO PCT/AU2009/001367 patent/WO2010042997A1/en active Application Filing
- 2009-10-16 BR BRPI0914504A patent/BRPI0914504B8/en active IP Right Grant
- 2009-10-16 DK DK09820116.3T patent/DK2349320T3/en active
- 2009-10-16 AU AU2009304595A patent/AU2009304595B2/en active Active
- 2009-10-16 MX MX2011004031A patent/MX336384B/en unknown
- 2009-10-16 JP JP2011531304A patent/JP2012505835A/en active Pending
- 2009-10-16 EP EP09820116.3A patent/EP2349320B1/en active Active
- 2009-10-16 RU RU2011114857/15A patent/RU2519124C2/en active
- 2009-10-16 NZ NZ603602A patent/NZ603602A/en unknown
-
2011
- 2011-04-14 IL IL212353A patent/IL212353A0/en active IP Right Grant
- 2011-05-16 ZA ZA2011/03572A patent/ZA201103572B/en unknown
-
2012
- 2012-01-31 HK HK12100865.8A patent/HK1160598A1/en unknown
-
2013
- 2013-09-24 US US14/034,706 patent/US9238054B2/en active Active
-
2014
- 2014-11-25 IL IL235888A patent/IL235888A/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003105765A2 (en) * | 2002-06-12 | 2003-12-24 | The Board Of Trustees Of The University Of Illinois | Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds |
WO2004048401A1 (en) * | 2002-11-27 | 2004-06-10 | Itoham Foods Inc. | Peptides and medicinal compositions containing the same |
WO2006012394A1 (en) | 2004-07-21 | 2006-02-02 | Tulane University Health Sciences Center | Treatment of renal dysfunction and multiple myeloma using pacap compounds |
WO2007065226A1 (en) * | 2005-12-09 | 2007-06-14 | Vectus Biosystems Limited | Vip fragments and methods of use |
Non-Patent Citations (5)
Title |
---|
"The Science and Practice of Pharmacy, 19th Edition,", 1995, MACK PUBLISHING CO. PENNSYLVANIA |
ARNAOUT M.A. ET AL.: "Prolactin responses to vasoactive intestinal polypeptide and thyrotropin releasing hormone in chronic renal failure", ACTA ENDOCRINOLOGICA (COPENH), vol. 125, no. 6, 1991, pages 651 - 656, XP008147306 * |
BRITISH PHARMACOPOEIA, 2000 |
MEYER M. ET AL.: "Basic aspects of vasorelaxant and bronchodilating peptides in clinical use: Urodilatin, VIP and PACAP", ANNALS NEW-YORK ACADEMY OF SCIENCES, vol. 805, 1996, pages 443 - 461, XP008147282 * |
See also references of EP2349320A4 |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9458218B2 (en) | 2005-12-20 | 2016-10-04 | Duke University | Therapeutic agents comprising fusions of insulin and elastic peptides |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US10258700B2 (en) | 2005-12-20 | 2019-04-16 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US9328154B2 (en) | 2005-12-20 | 2016-05-03 | Duke University | Therapeutic agents comprising fusions of growth hormone and elastic peptides |
US8729018B2 (en) | 2005-12-20 | 2014-05-20 | Duke University | Therapeutic agents comprising elastic peptides |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US11103558B2 (en) | 2008-06-27 | 2021-08-31 | Duke University | Therapeutic agents comprising a BMP-9 peptide and eleastin-like peptides |
US10596230B2 (en) | 2008-06-27 | 2020-03-24 | Duke University | Methods of increasing nutrient absorption in the intestine using therapeutic agents comprising GLP-2 and elastin-like peptides |
US9821036B2 (en) | 2008-06-27 | 2017-11-21 | Duke University | Therapeutic agents comprising a GLP-2 peptide and elastin-like peptides |
US8729020B2 (en) | 2009-04-02 | 2014-05-20 | Vectus Biosystems Pty Ltd | Methods for the treatment of aortic fibrosis with VIP fragments |
WO2010111753A1 (en) * | 2009-04-02 | 2010-10-07 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of aortic fibrosis |
AU2010230862B2 (en) * | 2009-04-02 | 2014-04-17 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of aortic fibrosis |
US10337008B2 (en) | 2010-10-01 | 2019-07-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods for predicting the progression and treating a chronic kidney disease in a patient |
WO2012042061A1 (en) * | 2010-10-01 | 2012-04-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the progression and treating a chronic kidney disease in a patient |
WO2016145478A1 (en) | 2015-03-18 | 2016-09-22 | Vectus Biosystems Limited | Compositions for the treatment of kidney and/or liver disease |
AU2016232977B2 (en) * | 2015-03-18 | 2019-05-16 | Vectus Biosystems Limited | Compositions for the treatment of kidney and/or liver disease |
US10183908B2 (en) | 2015-03-18 | 2019-01-22 | Vectus Biosystems Limited | Compositions for the treatment of kidney and/or liver disease |
EP3271326A4 (en) * | 2015-03-18 | 2018-10-31 | Vectus Biosystems Limited | Compositions for the treatment of kidney and/or liver disease |
Also Published As
Publication number | Publication date |
---|---|
NZ592612A (en) | 2013-01-25 |
ES2603963T3 (en) | 2017-03-02 |
US20140080758A1 (en) | 2014-03-20 |
MX2011004031A (en) | 2011-06-27 |
SG10201501316VA (en) | 2015-05-28 |
CN102186496A (en) | 2011-09-14 |
RU2011114857A (en) | 2012-11-27 |
JP2012505835A (en) | 2012-03-08 |
BRPI0914504B1 (en) | 2020-11-10 |
BRPI0914504A2 (en) | 2016-01-12 |
AU2009304595B2 (en) | 2015-02-05 |
RU2519124C2 (en) | 2014-06-10 |
IL212353A0 (en) | 2011-06-30 |
MY160560A (en) | 2017-03-15 |
EP2349320B1 (en) | 2016-06-22 |
EP2349320A1 (en) | 2011-08-03 |
CA2740989A1 (en) | 2010-04-22 |
BRPI0914504B8 (en) | 2021-05-25 |
KR20110095266A (en) | 2011-08-24 |
NZ603602A (en) | 2013-09-27 |
KR101671406B1 (en) | 2016-11-01 |
DK2349320T3 (en) | 2016-09-26 |
AU2009304595A1 (en) | 2010-04-22 |
US20110218149A1 (en) | 2011-09-08 |
US8569235B2 (en) | 2013-10-29 |
US9238054B2 (en) | 2016-01-19 |
CA2740989C (en) | 2016-07-12 |
HK1160598A1 (en) | 2012-08-10 |
EP2349320A4 (en) | 2012-12-26 |
IL235888A (en) | 2017-08-31 |
ZA201103572B (en) | 2012-01-25 |
MX336384B (en) | 2016-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9238054B2 (en) | Treatment of kidney fibrosis with VIP fragments | |
EP2783697B1 (en) | VIP Fragments and uses thereof | |
AU2005251386B8 (en) | Compositions and methods for treatment of cardiovascular disease | |
US20140235541A1 (en) | Compositions and methods for treatment of aortic fibrosis | |
JP5477794B2 (en) | Peptides derived from endokinin C / D |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980141074.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09820116 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011531304 Country of ref document: JP Ref document number: 12011500723 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 212353 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/004031 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2740989 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 592612 Country of ref document: NZ Ref document number: 2009304595 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3377/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13124139 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009820116 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117011192 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011114857 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009304595 Country of ref document: AU Date of ref document: 20091016 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 235888 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: PI0914504 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110414 |